MC
GILD icon

Moors & Cabot’s Gilead Sciences GILD Stock Holding History

Moors & Cabot’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-46,800
Closed -$30K – 647
2019
Q3 		$30K Buy
+46,800
New +$3.06M ﹤0.01% 624

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Moors & Cabot's GILD Position: Q2 2026 in Review

Moors & Cabot increased its Gilead Sciences (GILD) stake by 1.3% in Q2 2026, buying an estimated $31.4K and bringing the position to 18,919 shares worth $2.39M. The position accounts for 0.09% of the portfolio, ranked #198.

Moors & Cabot first reported a position in GILD in Q1 2014 and has held it in 50 quarters since. The position peaked at $3.25M in Q2 2015. 2,284 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Moors & Cabot held 18,919 shares of Gilead Sciences worth $2.39M as of Q2 2026.
  • Moors & Cabot bought 238 Gilead Sciences shares in Q2 2026, an estimated $31.4K.
  • Gilead Sciences made up 0.09% of Moors & Cabot's portfolio in Q2 2026, its #198 holding.
  • Moors & Cabot first reported a position in Gilead Sciences in Q1 2014 and has held it in 50 quarters since.
  • Moors & Cabot's Gilead Sciences position peaked at $3.25M in Q2 2015.
  • 2,284 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Moors & Cabot's 13F filing for Q2 2026, filed 10 Aug 2026.